Xavier Santamaria
Has grant
Investigador biomédico, especialidad ginecología
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Effect of CD133 Bone Marrow Derived Stem Cells on the maternal-fetal interface in patients with Asherman Syndrome
Open Date: 2023-09-01
Close Date: 2025-08-01
Grant: Close
Medical device to dIagnose pRenatal ad plACental disEases (MIRACLE)
Open Date: 2023-06-01
Close Date: 2026-06-01
Grant: Close
NUEVO TRATAMIENTO DE TERAPIA REGENERATIVA PARA PACIENTES CON SINDROME DE ASHERMAN
Open Date: 2020-01-01
Close Date: 2023-01-01
Grant: Close
Medicina regenerativa del útero humano: desde la terapia celular a la creación del órgano mediante bioingeniería.
Open Date: 2019-06-01
Close Date: 2022-12-01
Grant: Close
MEDICINA REGENERATIVA DEL ÚTERO HUMANO: DESDE LA TERAPIA CELULAR A LA CREACIÓN DEL ÓRGANO MEDIANTE BIOINGENIERÍA
Open Date: 2018-01-01
Close Date: 2021-12-01
Articles (8)
Year:
2026
Year:
2026
Year:
2025
Autologous CD133 + bone marrow-derived stem cell (BMDSC) therapy has been designated an Orphan Drug by the EMA and FDA for the treatment of Asherman Syndrome (AS). This phase 1/2, non-randomized, open-label, single-arm trial assessed the safety, efficacy and biological plausibility of this novel therapy in 20 infertile women with moderate to severe AS unresponsive to prior hysteroscopic treatments. The primary endpoint was safety, with doses ranging from 31 to 212 × 10⁶ cells being well tolerated; reversible limb paresthesia was the most common adverse event. Secondary endpoints demonstrated significant improvements in endometrial morphometry, thickness (3.80 ± 0.95 mm to 5.29 ± 0.77 mm, p < 0.05), endometrial volume (1.26 cm³ to 2.78 cm³, p < 0.05), and hysteroscopic scores (8.0 ± 3.17 to 4.42 ± 2.09, p < 0.05). Clinically, menstruation and reproductive function were restored, culminating in six live births following embryo transfer. Single-cell RNA sequencing of endometrium and organoids pre- and post-treatment revealed partial reversion of AS-related changes. Additionally, mitochondrial variant tracking offered insights into the engraftment of transplanted CD133 + BMDSCs. These findings suggest that autologous CD133 + BMDSC therapy is a safe and effective treatment for moderate to severe AS, warranting further investigation in larger trials.
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (11)
Hugo Vankelecom
Professor
KU Leuven
Anna Quirant Pellín
Profesora Tecnologia
Generalitat Valenciana Conselleria de Cultura Educació i Esport
Hugh Taylor
Chair Obstetrics and Gynecology
Yale University
Andrew W Horne
University of Edinburgh
Nilufer Rahmioglu
University of Oxford
Andres Salumets
Professor of reproductive medicine
Karolinska Institutet-Huddinge Campus
Carlos Simon
Professor of Obstetrics & Gynecology
Baylor College of Medicine
Jeannette Lager
Professor
University of California, San Francisco
Rosa Noguera
-
Sally Mortlock
University of Queensland
Philippa Saunders
Professor, Principal Investigator
University of Edinburgh
Make your next move.
Prepare your application
Review drafts before you send them.